CasNo.129453-61-8,Fulvestrant factory Low price from China,(129453-61-8) Suppliers

1 Gram	Negotiable

Min.Order :1 Gram
Purity: 99%min
Payment Terms : L/C,T/T

Keywords

Fulvestrant Fulvestrant BP/USP grade impurity

Quick Details

Appearance:white powder
Application:It’s a medication used to treat hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women with disease progression as well as HR-positive, HER2-negative advanced breast cancer i
PackAge:Special aluminum foil bag
ProductionCapacity:5|Kilogram|Month
Storage:2~8℃
Transportation:2~8℃

Superiority:

1.Production technique：we has more than 10 years’ experience to produce Fulvestrant,in which improve the technical maturity,make high yield of product and reduce the cost.

2.Impurities：all pharmacopoeia impurities are available.limit of any other unknown impurities is not more than 0.1%.

3.Key intermediates: Work of R&D of solid of key Ints. have been successed(as per documents’report, the appearance of these intermediates are oil mass,in which leads to the hard work of purification and quality control.)

4.The reaction temperature has risen -70℃ to -30℃ in the step of low temperature reaction,that is feasible for industrialized production.

Details:

Our very strong product. We are one of earliest developers in China. Could supply the complete intermediates

Fulvestrant, sold under the trade name Faslodex® among others, researched by Astra Zeneca, is a medication used to treat hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women with disease progression as well as HR-positive, HER2-negative advanced breast cancer in combination with palbociclib in women with disease progression after endocrine therapy.It was approved for medical use in the United States in April.25th,2002,and then in EMA on Mar.10,2004 and in Japan on Sep.26,2011.The dosage is 250mg of pre-filling oil injection.

Faslodex® was approved in China on 26th.Mar.,2015 and the dosage are 250mg and 5ml. No generic Faslodex available in China until now.

There are around 1.3million new breast cancer patients around the word every year and especially in China,incidence of female breast cancer increased by 47% in these recent 10 years, ranking No.1 in the urban women's tumors.The sales value of medicines of breast cancer reamin the same basically from 2009(US$10.2 million) to 2019(US$10.4million) in the USA,French,German,Italy,the U.K.and Japan according to the Decision Resources report.

In 2015,the world sales value of Fulvestrant is 70.4 million,ranking No.2 cance medicine in Astra Zeneca.

Tamoxifen (TMX), brand name Nolvadex, it’s currently used for the treatment of both early and advanced estrogen receptor (ER)-positive (ER+) breast cancer in pre- and post-menopausal women.However, Fulvestrant is more effective than Tamoxifen on following items:

A.Fulvestrant is a selective estrogen receptor degrader (SERD) and was first-in-class to be approved. It works by binding to the estrogen receptorand destabilizing it, causing the cell's normal protein degradation processes to destroy it. The affinity of estrogen receptor is 100 times as similar as that of Tamoxifen. It’s the only anti-estrogenic medicine that can be widely used for clinical treatment once the Tamoxifen failed.

B.It is as safe and effective as first line or second line endocrine therapy,taken once a month.